On December 01, 2025, a court hearing was held in Case No. SIP-298/2025, filed by AKRIKHIN against AstraZeneca Pharmaceuticals LLC seeking to declare their actions unfair competition and against AstraZeneca Pharmaceuticals LLC and the foreign entity AstraZeneca AB seeking to recognize the right to use the inventions and to compel them to refrain from impeding the medication introduction into circulation. During the case, AstraZeneca AB, a foreign entity, filed an independent claim for recognition of exclusive rights to the pharmaceutical composition.
Lawyers of «A.Zalesov & Partners» represented AKRIKHIN in the dispute.
Upon the consideration of the case, the Russian IP Court upheld the claims of AKRIKHIN and ruled:
1. To recognize the actions of ASTRAZENECA PHARMACEUTICALS, LLC, in sending letter No. 605/22-05-2024 to the Ministry of Health of the Irkutsk Region on May 22, 2024, and letter No. 599/14-05-2024 to the Ministry of Health of the Republic of Ingushetia on May 14, 2024, as an act of unfair competition, prohibited by Article 14.1 of Federal Law No. 135-FZ «On Protection of Competition» of July 26, 2006.
2. To oblige ASTRAZENECA PHARMACEUTICALS, LLC to refrain from sending letters containing information discrediting the activities of AKRIKHIN Chemical and Pharmaceutical Plant Joint Stock Company and/or the medicinal product Fordiglyph (registration certificate dated August 14, 2023, No. LP-No. (003001)-(RG-RU)).
3. To recognize the right of the joint-stock company «Chemical and Pharmaceutical Plant «AKRIKHIN» to use the invention under claim 16 of RU Patent No. 2262507, which has entered the public domain, namely, a compound having the claims
,
in the medicinal product «Fordiglyph» introduced into civil circulation (registration certificate dated August 14, 2023 No. LP-No. (003001)-(RG-RU)).
4. To recognize the right of the joint-stock company "Chemical and Pharmaceutical Plant «AKRIKHIN» to use the invention under claim 3 of RU Patent No. 2337916, which has entered the public domain, namely, a pharmaceutical composition with an inhibitory effect on SGLT2, comprising a compound having the structure
,
or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, in the medicinal product «Fordiglyph» introduced into civil circulation (registration certificate dated August 14, 2023 No. LP-No. (003001)-(RG-RU)).
5. To oblige ASTRAZENECA PHARMACEUTICALS, LLC, and AstraZeneca AB to refrain from creating obstacles for AKRIKHIN, a joint-stock company, to introduce into civil circulation the medicinal product Fordiglyph (registration certificate dated 14.08.2023 No. LP-No. (003001)-(RG-RU)) (INN Dapagliflozin), which uses the invention under claim 16 under RU Patent No. 2262507 and the invention under claim 3 under RU Patent No. 2337916.
The IP Court dismissed the independent claim of AstraZeneca AB to «recognize the exclusive right of the foreign entity AstraZeneca AB to use in the Russian Federation a pharmaceutical composition with SGLT2 inhibitory activity, comprising a compound of the claims
and a pharmaceutically acceptable carrier, for the term of validity additional Russian Federation patent No. 2746132».
The operative part of the court's decision was announced at the hearing on December 01, 2025. The IP Court's decision enters into legal force on the date of its adoption and is subject to immediate execution.
The client's interests in the case were represented by Aleksey Zalesov, Head of Intellectual Property Practice, and Darya Kushnarenko, Senior Associate.